Clinical characteristics of long-term survivors following sorafenib treatment for unresectable hepatocellular carcinoma: Korean national multicenter retrospective cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Young Youn | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Paik, Yong-Han | - |
dc.contributor.author | Bae, Si Hyun | - |
dc.contributor.author | Park, Su Cheol | - |
dc.contributor.author | Kim, Kang Mo | - |
dc.contributor.author | Jang, Eun Sun | - |
dc.contributor.author | Kim, In Hee | - |
dc.contributor.author | Kim, Hyung Jun | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.date.accessioned | 2023-03-08T15:47:02Z | - |
dc.date.available | 2023-03-08T15:47:02Z | - |
dc.date.issued | 2018-11 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.issn | 1440-1746 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/63826 | - |
dc.description.abstract | Background/Aim: Sorafenib is the first systemic therapy for the treatment of advanced-stage hepatocellular carcinoma (HCC) and progressive HCC after locoregional therapy. The aim of this study was to evaluate the prognostic factors of long-term survivors after sorafenib treatment. Methods: This multicenter, retrospective, cohort study included 1,566 unresectable HCC patients who received sorafenib treatment between 2007 and 2014 in nine tertiary centers in Korea. The patients were classified into a long-term survivor group (survival more than two years, n = 257) or a control group (n = 1309). The primary outcomes were the prognostic factors affecting long-term survival. Secondary endpoints included time-to-progression and other safety profiles. Results: The patients were predominantly men (83.8%) with chronic hepatitis B (77.3%) and Barcelona clinic of liver cancer-stage C (BCLC-C) (78.3%). The median overall survival was 9.0 months. After treatment, eight patients (0.4%) achieved complete response and 139 patients (8.8%) achieved partial response according to the mRECIST criteria. The prognostic factors predicting long-term survival were metformin use (adjusted hazard ratio [aHR] = 3.464; P < 0.001), hand-foot skin reaction (aHR = 1.688; P = 0.003), and concomitant treatment with chemoembolization or radiotherapy (aHR = 2.766; P < 0.001). Poor prognostic factors of long-term survival were a Child-Pugh score of B (HR = 0.422; P < 0.001), the presence of extrahepatic metastasis (HR = 0.639; P = 0.005), main portal vein invasion (HR = 0.502; P = 0.001), and elevated alpha-fetoprotein (>1,000 ng/mL; HR = 0.361; P < 0.001). Conclusion: This large, multicenter, retrospective study showed an objective response rate of 9.1% and a proportion of long-term survivors of 16.4% in Korean patients. The prognostic factors derived in our study can be used in clinical practice during sorafenib treatment. | - |
dc.format.extent | 1 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Clinical characteristics of long-term survivors following sorafenib treatment for unresectable hepatocellular carcinoma: Korean national multicenter retrospective cohort study | - |
dc.type | Article | - |
dc.identifier.doi | 10.2147/JHC.S304439 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, v.33, pp 69 - 69 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000450260400072 | - |
dc.citation.endPage | 69 | - |
dc.citation.startPage | 69 | - |
dc.citation.title | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.volume | 33 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | good responder | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordAuthor | sorafenib | - |
dc.subject.keywordAuthor | survivor | - |
dc.subject.keywordPlus | ALPHA-FETOPROTEIN | - |
dc.subject.keywordPlus | LIVER-CANCER | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | PREDICT | - |
dc.subject.keywordPlus | SAFETY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.